Literature DB >> 9714142

Insulin and 2-hour glucose levels are inversely related to Lp(a) concentrations controlled for LPA genotype.

D L Rainwater1, S M Haffner.   

Abstract

In this study we assessed the relationship of lipoprotein(a) [Lp(a)] with diabetes status and with measures of glucose and insulin in a population of Mexican Americans having a high prevalence of non-insulin-dependent diabetes mellitus (NIDDM). Because of enormous allelic diversity at LPA [the locus encoding the apo(a) protein] that directly influences Lp(a) concentrations, it was first necessary to adjust for the large effects of variation at LPA. We calculated residual Lp(a) concentration as the difference between observed and expected; expected Lp(a) concentration was based on information from all family members sharing each identical-by-descent (IBD) allele. We found significant effects of sex and age on residual Lp(a) concentrations that increased with age (P=0.0004) and in females (P=0.0034). Although diabetes status per se was not related to residual Lp(a) concentrations (P=0.097), we found that residual Lp(a) concentrations were inversely correlated with fasting insulin (P=0.0017) and with insulin (P=0.0028) and glucose (P=0.0429) concentrations measured 2 hours after a glucose challenge. Furthermore, significant inverse correlations with the 2 insulin measures were observed for a subgroup of nondiabetic individuals. Inclusion of 2 lipid measures (plasma concentrations of cholesterol and triglycerides) in the models showed that the correlations with insulin and glucose were independent of the relationship between Lp(a) concentrations and the lipid measures. Also, we determined the residual size for each apo(a) isoform by adjusting for the IBD isoform group average. Although not related to diabetes status, residual apo(a) isoform size was positively correlated with fasting insulin (P=0.0013) and with 2-hour glucose (P=0.0246) and 2-hour insulin (P=0.0182) concentrations. In addition, significant correlations for all 4 measures were found for the subgroup of nondiabetic individuals. Thus, the results demonstrate that glucose-intolerant individuals have significantly lower residual Lp(a) concentrations and a significant increase of residual apo(a) size.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9714142     DOI: 10.1161/01.atv.18.8.1335

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  25 in total

1.  Lipoprotein(a) in type 2 diabetic subjects and its relationship to diabetic microvascular complications.

Authors:  Radhakrishnan Chandni; Kollengode Parameswaran Ramamoorthy
Journal:  World J Diabetes       Date:  2012-05-15

2.  Long-term statin therapy could be efficacious in reducing the lipoprotein (a) levels in patients with coronary artery disease modified by some traditional risk factors.

Authors:  Ming-Xing Xu; Chang Liu; Yong-Ming He; Xiang-Jun Yang; Xin Zhao
Journal:  J Thorac Dis       Date:  2017-05       Impact factor: 2.895

3.  Genetic variants, plasma lipoprotein(a) levels, and risk of cardiovascular morbidity and mortality among two prospective cohorts of type 2 diabetes.

Authors:  Qibin Qi; Tsegaselassie Workalemahu; Cuilin Zhang; Frank B Hu; Lu Qi
Journal:  Eur Heart J       Date:  2011-09-06       Impact factor: 29.983

4.  Lipoprotein(a) and risk of type 2 diabetes.

Authors:  Samia Mora; Pia R Kamstrup; Nader Rifai; Børge G Nordestgaard; Julie E Buring; Paul M Ridker
Journal:  Clin Chem       Date:  2010-05-28       Impact factor: 8.327

5.  Levels of sex steroid and cardiovascular disease measures in premenopausal and hormone-treated women at midlife: implications for the "timing hypothesis".

Authors:  MaryFran R Sowers; John Randolph; Mary Jannausch; Bill Lasley; Elizabeth Jackson; Daniel McConnell
Journal:  Arch Intern Med       Date:  2008-10-27

6.  Fatty liver disease: Disparate predictive ability for cardiometabolic risk and all-cause mortality.

Authors:  Altan Onat; Günay Can; Ayşem Kaya; Tuğba Akbaş; Fatma Özpamuk-Karadeniz; Barış Şimşek; Hakan Çakır; Hüsniye Yüksel
Journal:  World J Gastroenterol       Date:  2015-12-28       Impact factor: 5.742

Review 7.  Lipoprotein (a): impact by ethnicity and environmental and medical conditions.

Authors:  Byambaa Enkhmaa; Erdembileg Anuurad; Lars Berglund
Journal:  J Lipid Res       Date:  2015-12-04       Impact factor: 5.922

8.  Lipoprotein(a) and cardiovascular disease in diabetic patients.

Authors:  Qibin Qi; Lu Qi
Journal:  Clin Lipidol       Date:  2012-08

Review 9.  Lipoprotein(a): novel target and emergence of novel therapies to lower cardiovascular disease risk.

Authors:  Sotirios Tsimikas
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2016-04       Impact factor: 3.243

10.  The association between circulating lipoprotein(a) and type 2 diabetes: is it causal?

Authors:  Manjinder S Sandhu; Nita G Forouhi; Zheng Ye; Philip C Haycock; Deepti Gurdasani; Cristina Pomilla; S Matthijs Boekholdt; Sotirios Tsimikas; Kay-Tee Khaw; Nicholas J Wareham
Journal:  Diabetes       Date:  2013-10-02       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.